These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1195 related items for PubMed ID: 8635111

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):664-73. PubMed ID: 11849788
    [Abstract] [Full Text] [Related]

  • 4. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA, Stock RG, Stone N.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):645-53. PubMed ID: 14529768
    [Abstract] [Full Text] [Related]

  • 5. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate.
    Stone NN, Ramin SA, Wesson MF, Stock R, Unger P, Klein G.
    J Urol; 1995 May 01; 153(5):1555-60. PubMed ID: 7536266
    [Abstract] [Full Text] [Related]

  • 6. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):600-7. PubMed ID: 21985944
    [Abstract] [Full Text] [Related]

  • 7. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
    Sharkey J, Chovnick SD, Behar RJ, Perez R, Otheguy J, Solc Z, Huff W, Cantor A.
    Urology; 1998 May 01; 51(5):796-803. PubMed ID: 9610594
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA.
    J Clin Oncol; 1999 Feb 01; 17(2):517-22. PubMed ID: 10080594
    [Abstract] [Full Text] [Related]

  • 9. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
    Sharkey J, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz R, Steele J, Webster C, Donohue M, Solc Z, Huff W, Cantor A.
    J Endourol; 2000 May 01; 14(4):343-50. PubMed ID: 10910150
    [Abstract] [Full Text] [Related]

  • 10. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS, Butler WM, Galbreath RW, Lief JH.
    Int J Radiat Oncol Biol Phys; 2001 Sep 01; 51(1):41-8. PubMed ID: 11516849
    [Abstract] [Full Text] [Related]

  • 11. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
    Zebentout O, Apardian R, Beaulieu L, Harel F, Martin AG, Vigneault E.
    Cancer Radiother; 2010 Jun 01; 14(3):183-8. PubMed ID: 20418145
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 14. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, See A, Duchesne GM.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):1889-96. PubMed ID: 21550182
    [Abstract] [Full Text] [Related]

  • 15. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG, Stone NN.
    Brachytherapy; 2002 Apr 01; 1(1):2-10. PubMed ID: 15062181
    [Abstract] [Full Text] [Related]

  • 16. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
    Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S.
    Int J Radiat Oncol Biol Phys; 1999 Aug 01; 45(1):59-67. PubMed ID: 10477007
    [Abstract] [Full Text] [Related]

  • 17. Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer.
    Stone NN, Stock RG, Unger P, Kao J.
    J Endourol; 2000 May 01; 14(4):375-80. PubMed ID: 10910155
    [Abstract] [Full Text] [Related]

  • 18. Prostate brachytherapy: treatment strategies.
    Stone NN, Stock RG.
    J Urol; 1999 Aug 01; 162(2):421-6. PubMed ID: 10411050
    [Abstract] [Full Text] [Related]

  • 19. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 01; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.